Glucocorticoid-induced osteoporosis

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 4, 2006, Pages 793-801

  De Gregório, Luiz Henrique ^a   Sampaio Lacativa, Paulo G ^a   Melazzi, Ana Cláudia C ^a   Russo, Luis Augusto Tavares ^a  

^a CCBR Brasil Center for Clinical and Basic Research   (Brazil)

Author keywords

Epidemiology; Fractures risk factors; Glucocorticoid adverse reactions; Osteoporosis; Review

Indexed keywords

EID: 33751221904     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302006000400024     Document Type: Review

References (61)

1. Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13(10):777-87.
2. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of corticosteroids and risk of fractures. J Bone Miner Res 2000;15(6):993-1000.
3. Adinoff AD, Hollister Jr. Steroid-induced fractures and bone loss in patients with asthma. N Eng J Med 1983;309(5):265-8.
4. Peat LJ, Healy S, Reid DM, Ralston SH. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis 1995;54(1):66-8.
5. Van Staa TP, Leufkens HGM, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroid in the United Kingdom. QJM 2000;93(2):105-11.
6. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140(10):4382-9.
7. Rubin J, Biskobing DM, Jadhav L, Fan D, Nanes MS, Perkins S, et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 1998;139(3):1006-12.
8. Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-b by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 2003;278(45):44667-74.
9. Lane NE, Roe B, Genant HK, Arnaud C. Parathyroid hormone treatment reverses glucocorticoid-induced osteoporosis: results of a randomized controlled trial. J Clin Invest 1998;102:1627-33.
10. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003;14(1):77-81.
11. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004;15(4):323-8.
12. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Fractures and oral corticosteroids: relationship to daily and cumulative dose. Rheumatol 2000;39:1383-9.
13. Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001;56:279-84.
14. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
15. Laan RFJM, van Riel PLCM, van de Pute LBA, van Erning LJTO, van't Hof MA, Lemmens JAM. Low dose predinisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993;119:963-8.
16. Manning PJ, Evans MC, Reid IR. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol 1992;36:229-34.
17. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependant asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-6.
18. Clowes JA, Peel N, Eastell R. Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2001;13:326-32.
19. Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 1996;11:676-85.
20. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Eng J Med 2001;345:941-7.
21. Van Staa TP, Leufkens HGM, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001;3:581-8.
22. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteoporosis of the hip. J Clin Endocrinol Metab 2000;85(8):2907-12.
23. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Min Reser 1994;9:1097-105.
24. Fucik RF, Kukrejas SC, Hargis GK, Bowser EN, Henderson WJ, Williams GA. Effect of glucocorticoids on function of parathyroid glands in man. J Clin Endocrinol Metab 1975;40:152-5.
25. Paz-Pacheco E, Fuleihan GE, LeBoff MS. Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J Bone Miner Reser 1995;10:1713-8.
26. Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence. J Clin Endocrinol Metab 2000;87(9):4033-41.
27. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990;150:2545-8.
28. Tsugeno H, Tsugeno H, Fujita T, Goto B, Sugishita T, Hosaki Y, et al. Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis. Osteoporos Int 2002;13(8):650-6.
29. Parisien M, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP, Dempster DW. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990;70:930-8.
30. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero N, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Min Reser 2001;16(1):97-103.
31. Parisien M, Mellish RW, Silverberg SJ, Shane E, Lindsay R, Bilezikian JP, et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Reser 1992;7:913-9.
32. Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A, et al. High-dose glucocorticoid treatment induces rapid bone loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006;17(1):105-8.
33. Elmstahl S, Ekstrom H, Galvard H, Johnell O, Gerhardsson de Verdier M, Norjavaara E. Is there an association between inhaled corticosteroids and bone density in postmenopausal women? J Allergy Clin Immunol 2003;111(1):91-6.
34. Van Staa TP, Bishop N, Leufkens HGM, Cooper C. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int 2004;15(10):785-91.
35. Shane E, Rivas M, McMahon DJ, Staron RB, Silverberg SJ, Seibel MJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 1997;82(5):1497-506.
36. Teichmann J, Lange U, Stracke H, Federlin K, Bretzel RG. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int 1999;18:137-40.
37. Maricic M, Gluck O. Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitom 2004;7(4):359-63.
38. Selby PL, Halsey JP, Adams KRH. Corticosteroids do not alter the threshold for vertebral fracture. J Bone Min Reser 2000;15:952-6.
39. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. 2001 Recommendation for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001;44(7):1496-503.
40. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998;83:801-6.
41. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP. et al. The course of biochemical parameters of boné turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991;72:382-6.
42. Chiodini I, Carnevale V, Torlontano M, Fusilli S, Guglielmi G, Pileri M, et al. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess, study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 1998;83(6):863-7.
43. Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004;89(10):4923-8.
44. Sasaki N, Kusano E, Ando Y, Nemoto J, Iimura O, Ito C, et al. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 2002;30(6):853-8.
45. Paglia F, Dionisi S, De Geronimo S, Rosso R, Romagnoli E, Raejntroph N, et al. Biomarkers of bone turnover after a short period of steroid therapy in elderly men. Clin Chem 2001;47(7):1314-6.
46. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low dose corticosteroid in patients with rheumatoid arthritis: a randomized double-blind, placebo controlled trial. Ann Intern Med 1996;125:961-86.
47. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Reser 2000;15:1006-13.
48. Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ, et al. Prophylactic use of alphacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999;9(1):75-81.
49. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004;15(4):301-10.
50. Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analisys of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004;15(8):589-602.
51. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Eng J Med 1998;339:292-9.
52. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
53. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
54. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000;11(4):331-7.
55. Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 2004;59:761-8.
56. Luengo M, Pons F, Martinez de Osaba JM, Picado C. Prevention of further bone mass loss by nasal calcitoninin patients on long term glucocorticoid therapy for asthma: a two-year follow-up study. Thorax 1994;49:1099-102.
57. Adachi JD, Bensen WG, Bell MJ, Bianchi FA, Cividino AA, Craig GL, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheum 1997;36(2):255-9.
58. Cauza E, Etemad M, Winkler F, et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther 2005;30(1):96.
59. Ringe J, Dorst A, Faber H, Ibach K, Preuss J. Three-monthly ibandronate bolus injection offers tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology 2003;42:743-9.
60. Ringe J, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003;14(10):801-7.
61. Aagard EM, Lin P, Modin GW, Lane NE. Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med 1999;107:456-60.